The enzyme sulfatase has been found to be able to catalyse a reaction it was presumed to be incapable of 1, expanding our understanding of biologically critical biomolecules. The discovery ...

此次获奖的NWU-CHINA-A团队由西北大学生命科学学院师生组成，雷蕾、李想、范铭沁、王弘靖、杨宇帆、瞿铱彤等6人赴法国巴黎参加线下盛会。2017年起，西北大学iGEM ...

Sep. 9, 2024 — Researchers tested a preclinical model for an experimental gene therapy designed to treat multiple sulfatase deficiency (MSD), a disorder that affects the brain, lungs ...

Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV ...

DNLI reports a wider-than-expected loss in the third quarter of 2024. Nonetheless, the pipeline progress has been encouraging.

Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV ...

Nov. 4, 2024 — Stem cells grown in microgravity aboard the International Space Station (ISS) have unique qualities that could one day help accelerate new biotherapies and heal complex disease ...

Reporting in the peer-reviewed journal Human Gene Therapy, researchers used ex vivo lentiviral gene therapy to treat mucopolysaccharidosis IVA (MPS ...

aro = aromatase, DOC = deoxycorticosterone, HSD = hydrosteroid dehydrogenase, HSO = hydrosteroid oxidoreductase, HSS = hydrosteroid sulfatase, KSR = ketosteroid reductase, R = reductase ...

Detailed price information for Denali Therapeutics Inc (DNLI-Q) from The Globe and Mail including charting and trades.